Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies - GBI Research Reports

Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies

Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies - GBI Research Reports
Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies
Published Mar 01, 2011
84 pages — Published Mar 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies that provides key data, information and analysis of the major trends and developments in preclinical studies and preclinical outsourcing business. The report provides a comprehensive insight into key technological developments, new approaches in developing preclinical models. The report talks about the key outsourcing business models and factors that are driving the global preclinical outsourcing market. The report also provides a detailed analysis of global preclinical market in terms of preclinical spending and preclinical outsourced value. The report also provides key alliances and acquisitions related to preclinical studies among CROs.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Researchs team of industry experts.

Preclinical study is a critical stage in drug discovery and development. Preclinical study helps in developing a pharmacological profile of the drug and its acute toxicity. Preclinical testing involves lab and animal testing to determine if the drug is safe and effective enough for human testing and subsequent filing of Investigational New Drug (IND) application with FDA. Preclinical study makes use of systems or models such as in-vitro, in-vivo and in-silico models. These models in combination with screening, bio-imaging techniques and analytical technologies (LC, MS, LC-MS, bioanalysis) used for preclinical efficacy and safety studies.

There are latest advancements in technologies such as biomarker technology and nanotechnology that speed up the entire preclinical R&D process providing high quality preclinical data. Also the new approaches such as transgenic animal models, systems biology model and simulation models have provided solutions to various problems associated with preclinical research.

Pharmaceutical companies outsource their preclinical work to CROs to cut R&D costs; share associated risks; improve the preclinical data quality and to access specialized resources, talent pool and technology. Preclinical CROs are forming strategic partnerships and adopting innovative outsourcing business models. Global preclinical Spending is growing proportionately with the pharmaceutical R&D spending. The United States and top nine European Countries are the major preclinical outsourcing markets.

Scope

The scope of the report includes -
- Role of preclinical studies in drug discovery and development process
- Overview of current preclinical models, including in-vitro, in-vivo, in-silico models and supporting technologies
- Key technological developments and new approaches in developing preclinical models including case studies
- Outsourcing preclinical studies to CROs covering reasons for outsourcing, trends and key outsourcing business models including case studies
- Market characterization of global preclinical outsourcing market including preclinical spending and preclinical outsourced value
- Preclinical outsourcing market forecast, 2009-2016
- Geographical analysis including top nine European countries and the United States.
- Key drivers and restraints that have a significant impact on the market
- Competitive benchmarking of 16 leading CROs, covering their preclinical service offerings and recent deals in preclinical research

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -
- Compare the key capabilities and mod

  
Source:
Document ID
GBIHC068MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents35
  List of Tables61
  List of Figures71
Preclinical Models Introduction81
  GBI Research Report Guidance81
Preclinical Models- Market Overview98
  Drug Discovery and Development- An overview91
    Drug Discovery101
    Preclinical Study/Development101
    Clinical Development111
      The Phases of a Clinical Trial111
  Preclinical Studies- An overview121
  Preclinical Study Design and Planning121
    Preclinical Study - Strategic Planning121
    Key Considerations during Preclinical Study Design131
      Establishment of Rationale131
      Identification and Selection of a Clinical Indication131
      Selection of an Appropriate Species131
      Pharmacodynamic and Pharmacokinetic Parameters131
      Characterization of Toxicities131
  Preclinical Studies- In-house141
  Preclinical Studies- Outsourced141
    Independent Contracting141
    Complete Outsourcing141
  Role of a CRO151
  Regulatory Aspects of Preclinical Studies161
    The Principles of Good Laboratory Practice161
    NIH and AAALAC161
Preclinical Models- Preclinical Outsourcing Models1710
  Reasons for Outsourcing Preclinical Studies171
    Optimizing Cost181
    Achieving Speed and Flexibility181
    Access to Specialty Resources, Technological Advancements, Equipment and Facilities181
    Minimizing the Risks Associated with the Early Stages of the Drug Discovery Development Process181
    Focus on Core Competencies191
  Preclinical Outsourcing Process191
    Steps Involved In Outsourcing a Preclinical Project191
      Planning and Preparation191
      Planning for the Investigational New Drug (IND) Application191
      Designing Individual Studies and Preparation of Technical Manuals191
      Selection of a CRO201
      Legal Agreements201
    Criteria for Selecting a Contract Research Organization211
    Preclinical Outsourcing Business Models221
      Independent Contracting (Functional Business/Service Model)221
      Complete Outsourcing (Fully Integrated Business/Service Model)231
  Outsourcing Trends231
    Strategic Partnerships and R&D collaborations with Pharmaceutical Companies231
    Capacity Concerns241
    Innovative Management of Outsourcing Projects241
    Strategic Shift in Funding and Payment Patterns241
    Emergence of One-Stop-Shop CROs and Boutique Providers 241
  Case Studies251
    Early Stage Preclinical Project251
    Long Term Partnerships with Drug Discovery and Preclinical Service Providers261
Preclinical Models- Technology Landscape2715
  Current System271
    Overview271
    Key Technologies271
      Nuclear Magnetic Resonance (NMR)271
      X-Ray Crystallography281
      Scintillation Proximity Screening Assay281
      Radiometric Binding Assay281
      Non-Radiometric Assay281
      Microfluidics Systems281
    In-Vitro ADMET Screening Models281
    In-vivo ADMET Screening Models291
      Vertebrate Models291
      Invertebrate Models301
    In-silico ADMET Screening models301
      Protein Modeling301
      Combinatorial Chemistry Applications301
      Data Mining (Data-Based Approach)311
  Trends in Technology Models311
    Recent Technology Developments311
      Biomarkers311
      Nanotechnology321
    New Approaches331
      Genomics, Proteomics and Metabolomics (Omics-technologies)331
      Systems Biology/Toxicogenomics Approach341
      Surgical Models341
      Transgenic Animal Models341
      Simulation Models341
  Case Studies-Preclinical Models (Technological Developments)351
    Apredica s Customized In-vitro ADMET Screening Assays351
    AVEO Pharmaceuticals Breakthrough with Transgenic Mouse Model for Human Breast Cancer361
    In-vitro Models for Dermal Corrosion / Irritation and Eye Irritation by Charles River371
    Preclinical Models of Hepatocellular Carcinoma and Biomarker Strategy by Pfizer381
    SimuGen s HT-Stream, a Preclinical Toxicogenomics System/Model391
    A Validated Physiologically Based Mathematical Model of Pathogenesis in the Non-Obese Diabetic Mouse by Entelos391
    Simulation Modeling to Treat Spinal Cord Injuries by Novartis401
    Recent Development in Preclinical Imaging by Caliper Life Sciences411
Preclinical Models- Market Characterization425
  Global Spending on Prehuman/Preclinical Studies421
  Preclinical Spending by Geography431
  Global Preclinical Outsourcing Market441
  Key Market Drivers and Restraints451
    Market Drivers451
      Increasing R&D Expenditure451
      Globalization and Outsourcing Advantages in Asian Countries451
      Laboratory Animal Supply461
    Key Restraints461
      Economic Slowdown has Flattened the Demand for Outsourcing Toxicology Studies461
      Problems Associated with Recruiting an Experienced Talent Pool461
Preclinical Models- Geographical Analysis4710
  Germany471
  The UK481
  Switzerland491
  Italy501
  France511
  Belgium521
  Denmark531
  Spain541
  Sweden551
  The US561
Preclinical Models- Company Profiling5723
  Charles River Laboratories International, Inc.571
    Business Overview571
    Recent M&A Deals and Strategic Alliances in Preclinical Research581
      Charles River Entered a Long-term Licensing Agreement with Transposagen Biopharmaceuticals.581
      Charles River Laboratories Acquired Piedmont Research Center581
      Charles River Acquired Cerebricon Ltd.581
      Charles River Acquired MIR Preclinical Services581
  Cyprotex Discovery Ltd.591
    Business Overview601
    Recent M&A Deals and Strategic Alliances in Preclinical Research601
      Cyprotex and TB Alliance Form Collaboration to Accelerate the Discovery of New TB Drugs601
      Cyprotex Acquired Apredica LLC601
  Shanghai ChemPartner611
    Business Overview611
    Recent M&A Deals and Strategic Alliances in Preclinical Research611
      ChemPartner Entered a Strategic Partnership with Shanghai Clinical Research Center611
      Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration611
  Covance, Inc.621
    Business Overview621
    Recent M&A Deals and Alliances in Preclinical Research631
      Covance Entered into a Strategic R&D Agreement with Sanofi-Aventis631
      Covance Entered into Biomarker Alliance With Rules-Based Medicine, Inc.631
      Covance Agreed to Provide Genomic Analysis Services to Merck &Co., Inc.631
      Covance Entered into a Multi-Year Marketing Agreement with Phase Forward631
  PPD, Inc.641
    Business Overview641
    Recent M&A Deals and Alliances in Preclinical Research641
      PPD Entered into a Collaboration with Lovelace Biomedical and Environmental Research Institute641
      PPD Acquired Magen BioSciences641
      PPD Enters Into Strategic Collaboration with Merck641
  Ricerca Biosciences, LLC651
    Business Overview651
    Recent M&A Deals and Strategic Alliances651
      Ricerca Biosciences Acquired MDS Pharma Services651
  Caliper Life Sciences661
    Business Overview661
    Recent M&A Deals and Strategic Alliances in Preclinical Research671
      Caliper Formed a Strategic Collaboration with the Peter MacCallum Cancer Centre671
      Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for GPCR Profiling671
      Caliper Life Sciences Inc. Formed Alliance with Horizon Discovery671
  GVK BIO681
    Business Overview681
    Recent M&A Deals and Strategic Alliances in Preclinical Research691
      GVK BIO and Crelux Collaboratively Set Up Fragment-Based Drug Discovery Platform691
      GVK BIO Entered into a Drug Discovery Agreement with Wyeth Pharmaceuticals691
      GVK BIO Licensed its Medicinal Chemistry Database (MCD) to GeneGo691
  MPI Research701
    Business Overview701
    Recent M&A Deals and Strategic Alliances in Preclinical Research701
      MPI Research Formed a Strategic Collaboration with Kineta701
  MDS711
    Business Overview711
  MD Biosciences721
    Business Overview721
    Recent M&A Deals and Strategic Alliances in Preclinical Research721
      MD Biosciences Formed Collaboration with PharmaGap721
  Aptuit731
    Business Overview731
    Recent M&A Deals and Strategic Alliances in Preclinical Research731
      Aptuit Acquires GSK s R&D Operations in Italy731
      Aptuit Formed Collaboration with Taiwan Liposome Company (TLC)731
  ITR Canada741
    Business Overview741
  Advinus Therapeutics751
    Business Overview751
    Recent M&A Deals and Strategic Alliances761
      Advinus Established a Collaboration with Ortho-McNeil-Janssen Pharmaceuticals761
      Advinus, Genzyme Corporation and Medicines for Malaria Venture (MMV) Establish New Collaboration761
      Advinus and DNDi Formed Alliance761
      Samaritan Pharma Entered Service Agreement with Advinus Therapeutics.761
  Jubilant Biosys771
    Business Overview771
    Major M&A Deals and Strategic Alliances781
      Jubilant Biosys Entered a Co-Marketing Agreement with DiscoveRx781
      Jubilant Biosys and Endo Pharmaceuticals formed an R&D Collaboration781
      Jubilant Entered Research Collaboration with AstraZeneca781
      Jubilant and Orion Established "Hybrid and Integrated " Discovery Collaboration781
      Jubilant and BioLeap Formed New Partnership in Drug Discovery781
  AMRI791
    Business Overview791
    Recent Deals in Preclinical Research791
      Drug Discovery Research Collaboration with Bristol-Myers Squibb Company791
Preclinical Models- Appendix805
  Market Definitions801
  List of Abbreviations811
  Research Methodology822
    Coverage821
    Secondary Research821
    Primary Research831
    Expert Panel Validation831
  Contact Us831
  Disclaimer831
  Sources841

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies" Mar 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Preclinical-Models-Preclinical-CROs-will-Continue-to-Improve-the-Quality-and-Accuracy-of-Data-for-Targeted-Therapies-2115-171>
  
APA:
GBI Research Reports. (2011). Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies Mar 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Preclinical-Models-Preclinical-CROs-will-Continue-to-Improve-the-Quality-and-Accuracy-of-Data-for-Targeted-Therapies-2115-171>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.